Patient Access to Facility-Based Opioid Use Disorder Treatment in New Jersey in 2019

Research Report

Patient Access to Facility-Based Opioid Use Disorder Treatment in New Jersey in 2019

Abstract

Expanding access to effective treatment for opioid use disorder (OUD) is essential to staunching the opioid epidemic. This brief presents findings from the second round of a telephone survey that assessed patient access to treatment services for OUD at facilities that offered OUD pharmacotherapy (buprenorphine, methadone, or naltrexone) across New Jersey in 2019. We also monitor changes in access to treatment from 2018 to 2019. We present data on specific treatment service availability, wait times, and Medicaid coverage of treatment, including region- and county-specific data to assess the supply and demand of various treatment options throughout the state. We find the following:

  • Fifty-six percent of substance use treatment facilities offered any form of OUD pharmacotherapy in 2019, up from 49 percent in 2018. 
  • Treatment facilities offering OUD pharmacotherapy remained concentrated in Northern New Jersey. 
  • Patients faced a median wait time of two days across all counties and services, though wait times varied widely across both county and service type.
Research Area: 

Centers

To reuse content from Urban Institute, visit copyright.com, search for the publications, choose from a list of licenses, and complete the transaction.